FindMyKOL
Clinical trialNCT05296070RecruitingPhase 2Interventional

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

SponsorUniversity of MiamiEnrollment50Marginal Zone Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope National Medical Center

    Duarte, California, United States

    Geoffrey Shouse, DO, PhD
    Recruiting
  • University of Miami

    Miami, Florida, United States

    Izidore Lossos, MD
    Recruiting
  • Emory University

    Atlanta, Georgia, United States

    Jean L Koff, MD
    Recruiting
  • Vanderbilt University

    Nashville, Tennessee, United States

    Olalekan Oluwole, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Loncastuximab tesirine 150 µg/KgLoncastuximab tesirine 75µg/Kg
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Jun 2022
Primary completion
30 Jun 2028
Completion
30 Jun 2029
Last update posted
30 Sept 2025
Registered enrollment
50
Registry id
NCT05296070
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.